key: cord-0751139-xlnkgfu3
authors: Magro, C.; Mulvey, J.J.; Laurence, J.; Sanders, S.; Crowson, N.; Grossman, M.; Harp, J.; Nuovo, G.
title: The differing pathophysiologies that underlie COVID‐19 associated perniosis and thrombotic retiform purpura: a case series
date: 2020-07-22
journal: Br J Dermatol
DOI: 10.1111/bjd.19415
sha: d25dc28c34c369e4f34d7871c3617bc7152f4432
doc_id: 751139
cord_uid: xlnkgfu3

BACKGROUND: There are two distinctive acral manifestations of COVID‐19 embodying disparate clinical phenotypes: one is perniosis occurring in mildly symptomatic patients, typically children; the second is the thrombotic retiform purpura of critically ill COVID19 adults. MATERIALS AND METHODS: We compare light‐microscopic, phenotypic, cytokine, and SARS‐CoV‐2 protein and RNA profiles in COVID‐19‐associated perniosis of mildly symptomatic or asymptomatic patients with the thrombotic retiform purpura of critical patients with COVID‐19. RESULTS: The COVID‐19‐associated perniosis exhibited vasocentric and eccrinotropic T‐cell and monocyte‐derived CD11c, CD14, and CD123+ dendritic cell infiltrates. Both COVID associated and idiopathic perniosis showed striking expression of the type I interferon‐inducible myxovirus resistance protein‐A (MXA), an established marker for type I interferon signaling in tissue. SARS‐CoV‐2 RNA, IL‐ 6 and caspase 3 were minimally expressed and confined to mononuclear inflammatory cells. The biopsies from livedo/retiform purpura showed pauci‐inflammatory vascular thrombosis without any MXA decoration. Blood vessels exhibited extensive complement deposition with endothelial cell localization of SARS‐CoV‐2 protein, IL6, and caspase 3; SARS CoV‐2 RNA was not seen. CONCLUSION: The COVID‐19‐associated perniosis represents an exaggerated immune reaction to a virus with significant type‐I interferon signaling important to SARS‐CoV‐2 eradication and has implications in regards to a more generalized highly‐inflammatory response. We hypothesize that in the thrombotic retiform purpura of critically ill patients with COVID‐19, the vascular thrombosis in the skin and other organ systems is associated with a minimal interferon response allowing excessive viral replication with release of viral proteins that localize to extrapulmonary endothelium and trigger extensive complement activation.

elderly and patients with certain pre-existing conditions such as diabetes , hypertension and obesity where higher mortality rates have been observed. 4 We recently reported that a complement-driven pauci-inflammatory thrombotic form of septal capillary injury causes severe progressive acute respiratory distress syndrome (ARDS) in the setting of COVID-19. 5 We showed that patients critically ill with COVID- 19 have widespread systemic complement activation destorying microvasculature and exacerbating concurrent thrombophilia resulting in organ dysfunction attributable to vascular thrombosis. This type of complement driven thrombotic syndrome is not recognized as a complication of COVID-19 in the pediatric setting where the clinical course is typically banal 6 . Uncommonly however, children can develop perniosis or a multisystemic inflammatory syndrome resembling Kawasaki's disease in response to SARS-CoV-2 infection. 7-12 .

The skin is an easily accessible window to understand the pathophysiologic basis of COVID-19 and its heterogeneous clinical phenotype. One pole of the cutaneous spectrum is the perniosis-like acral dermatitis occurring predominantly in children and less commonly in adults, who present with no or mild additional symptoms of viral infection such as cough or low-grade fever. For purposes of this paper we will designate this eruption as "COVID-19 associated perniosis" defining it as a form of virally triggered perniosis to distinguish it from cold induced ("idiopathic") perniosis 13 . The opposite pole, COVID-19-associated thrombotic livedo/retiform purpura, is a cutaneous extension of the severe microangiopathic ARDS seen in the critically ill 5 . The hallmarks are a pauci-inflammatory thrombogenic vasculopathy associated with activation of the mannan binding lectin and alternative complement pathways.

We describe 3 cases of COVID-19 associated perniosis and compare them with 6 cases of idiopathic perniosis and 6 cases of thrombotic retiform purpura seen in critically ill COVID-19 patients from a clinical, light microscopic, immunophenotypic, viral and molecular perspective. We propose that COVID-19 associated perniosis represents a virally induced archetypical interferonopathy, reflective

This article is protected by copyright. All rights reserved of the robust immune response typical of children and mechanistically distinct from the interferon poor complement driven retiform purpura encountered in very sick patients with COVID-19 13 .

Cases of perniosis were sectioned at a thickness of 5 μm and stained on positively charged glass slides stored at 4°C within 3 days after sectioning. Deparaffinization, rehydration, and antigen retrieval were performed on the Bond-III Leica automated slide stainer following the methodologies that have been previously described 15 Further viral studies were performed on the COVID-19 associated perniosis and COVID-19 livedo/retiform purpura cases and three cases of perniosis unrelated to COVID-19. Positive and negative controls used with every run included autopsy lung tissue from COVID-19 pneumonia patients and normal lung tissue obtained prior to 2019, respectively. Antibodies specific for the envelope protein (1:300) and spike protein (1:7000) of covid-19 (ProSci, Paway, CA) were optimized with the lung tissues; optimal pretreatment conditions included EDTA antigen retrieval solution (pH 9.0) for 30 minutes. The analyses were done on the automated Leica Bond platform with the modification that the Enzo Life Sciences peroxidase anti-mouse/rabbit conjugate (catalogue # ADI-950-113-0100) was used in place of the equivalent Leica conjugate as this reduced background.

Detection of SARS-CoV-2 RNA was done using the ACD RNAscope probe (Cat No. 848561-C3) as per a previously published protocol in which only the viral RNA probe is changed. The SARS-CoV-2

This article is protected by copyright. All rights reserved probe targets the target region nt 21631 -23303 derived from the genomic sequence of the virus ( NC_045512.2). In brief, pretreatment in the ACD RNA retrieval solution and protease digestion is followed by overnight hybridization at 37C and detection using the ACD 2.5 HD DAB detection kit

COVID-19 ASSOCIATED PERNIOSIS:

Case 1: A 16 year old male developed bilateral painful perniotic like plaques on his toes He had been confined to his home and denied any significant cold exposure. His brother had a cough and fever several weeks earlier which resolved without viral diagnostic testing (figure 1a). A nasopharyngeal swab was negative for SARS-CoV-2. Serologies to assess for past SARS-CoV-2 infection were not performed.

Case 2: A 48-year-old female resident of New City, New York developed fever, mild leukocytosis, a purpuric macular skin rash of the legs along with perniotic lesions on the toes. A skin biopsy was performed on one of the toe lesions. Her nasopharyngeal swab test for COVID-19 was negative. Her COVID-19 associated IgG and IgM serologies were also negative. 

The cases showed a similar morphology characterized by a mononuclear cell dominant interface dermatitis with an associated dense superficial and deep angiocentric lymphocytic and histiocytic infiltrate that surrounded and infiltrated the blood vessels and was adjacent to eccrine coil, ducts and glands ( figure 2a, figure 3a ). The histiocytes demonstrated reniform and serpiginous nuclei and intracytoplasmic cellular debris (figure 3a). Papillary dermal edema was seen in case one and three

This article is protected by copyright. All rights reserved (figure 2a). There was endothelial cell swelling and red cell extravasation. Fibrin deposition within reticular dermal based blood vessels was present but minimal.

Phenotypic studies demonstrated an infiltrate predominated by CD3 + T cells (figure 3b) and CD163+ CD68+ histiocytes. Rare CD20 positive B cells were seen (figure 3e). The CD4 to CD8 ratio was within normal limits ( figure 3c, figure 3d ). The histiocytes were highlighted by CD163, lysozyme, CD68, CD14 (figure 3f) CD11c (figure 3g), and CD123 (figure 3h); a subset was positive for myeloperoxidase. Significant MXA positivity in the epidermis, endothelia and inflammatory cells was seen in the three cases (figure 2c, 3i). Complement studies namely C3d, C4d, and C5b-9 were conducted and found to be either absent or minimally positive.

Six cases of idiopathic perniosis were retrieved from the archival files of the division of Dermatopathology, Weill Cornell Medicine. The biopsies were procured from 3 males and 3 females ranging in age from 16 years of age to 65 years of age. A diagnosis was made of idiopathic perniosis in all patients. The typical clinical presentation is illustrated in figure 1b and is characterized by discrete erythematous papules on the toes and or fingers. 

Skin biopsies of an acral fixed livedoid and/or retiform purpuric rash from SARS-Co-V2 positive patients were retrieved from the archival files of the division of dermatopathology, Weill Cornell

This article is protected by copyright. All rights reserved College of Medicine. The patient cohort was represented by 3 males who were 70,71 and 73 years of age and three females who were 36,40 and 66 years of age (figure 1c). Two of the patients developed a stroke. Acute renal injury developed in 4 of the 6 requiring dialysis in one. Pre-existing conditions included , hypertension in 3 overweightness in 2, obesity in 1, diabetes mellitus in 1 and hyperlipidemia in 1. The patients had acral livedoid rashes involving the hands bilaterally in 3, plantar aspect of the feet in 1 and forearms in two(figure 1c). All were categorized as being critically ill with COVID-19 based on prolonged ventilator dependent respiratory failure. They had evidence of a hypercoagulable state characterized by elevated D-Dimers ranging from 1026 ng/ml to 40135ng/ml (mean of 12027ng/ml )and fibrinogen ranging from 518 to 983 mg/dl (mean of 649 mg/dl) whereby there was a direct parallel between the extent of D-dimer elevation and fibrinogen elevation.. Of the 6 three died and three had hospitalizations of greater than 2 months.

The biopsies showed a pauci-inflammatory thrombogenic vasculopathy affecting capillaries, venules and arteries (figure 5a) within the mid and deeper dermis associated with microvascular deposition of C3d, C4d, C5b-9 and MASP-2 ( Figure 5d ). In all cases MXA was negative (figure 2e,5b).

In the three COVID-19 associated perniosis cases only rare SARS CoV-2 RNA positive cells were present (figure 3j) while a few mononuclear cells showed detectable SARS CoV-2 membrane and envelope protein (figure 3k). In all thrombotic retiform purpura cases, extensive SARS CoV-2 envelope and spike proteins were detected in the endothelial cytoplasms in thrombosed and normal appearing blood vessels (figure 5c) but not viral RNA. The three non-COVID-19 associated perniosis cases had no detectable protein or virus. As controls SARS-CoV-2 viral proteins/RNA was examined in the lung of the COVID-19 associated fatal pneumonias and normal skin/lung; it was extensively positive in the COVID-19 lung specimen and negative in the pre-COVID normal skin and lung blocks 

This article is protected by copyright. All rights reserved

In the 3 studied COVID-19 associated perniosis cases only a few cells of probable histiocytic origin expressed interleukin 6 (figure 3k). There were scattered inflammatory cells and degenerated keratinocytes positive for caspase 3. Vascular expression was noticeably absent. All cases of livedo/retiform purpura showed extensive endothelial cell expression of caspase 3 (figure 5e) and IL-6 (figure 5f) within the diseased and normal appearing blood vessels, mirroring the pattern of SARS CoV-2 associated protein detection.

We have outlined two disparate cutaneous manifestations of COVID-19: a highly inflammatory process with minimal vascular injury manifesting as acral perniosis without significant systemic symptoms designated as COVID-19 associated perniosis, versus a pauci-inflammatory thrombotic complement driven microvascular injury syndrome associated with microangiopathic ARDS. Idiopathic/familial perniosis, chilblains lupus, and Aicardi-Goutieres syndrome are associated with mutations in TREX1 and RNASEH2. Aicardi-Goutiere syndrome is associated with perniosis, periodic fevers, and microcephaly with progressive intellectual impairment due to a cerebral lymphocytic vasculitis. The end result of these mutations is excessive interferon signaling. It has been suggested that these nucleases are involved in removing nucleic acids that accumulate during apoptosis and when this process fails an interferon signal is generated and activates the immune system. MXA, the surrogate marker for type I interferon, would be expected to be significantly upregulated in idiopathic/familial perniosis, chilblains lupus and perniosis in the setting of Aicardi-Goutieres syndrome 21 .

In this current study, MXA was uniformly expressed in our cases of idiopathic/familial perniosis at high levels as revealed by striking MXA expression in the epidermis, endothelium and inflammatory

This article is protected by copyright. All rights reserved cells. The cases of COVID-19-associated perniosis showed extensive expression in the epidermis, endothelium, and inflammatory cells for MXA, similar to idiopathic perniosis and secondary perniosis in the setting of excessive interferon signaling (i.e. chilblains lupus and Aicardi Goutiere syndrome). The nature of the infiltrate in this small study cohort, being one rich in CD14+CD11C+ monocyte derived dendritic cells including many with a classic CD4+CD123+ plasmacytoid dendritic cell phenotype, activated myeloperoxidase positive macrophages, and T cells with only rare B cells is reflective of the type I interferon enriched microenvironment [22] [23] [24] The negative nasophyaryngeal swabs in our two COVID-19 perniosis patients may reflect the efficacy of interferon driven monocyte and T cell response to clear the virus in these patients and appears to be an almost ubiquitous finding in patients with COVID-19 associated perniosis 9,10,17-1 . Furthermore, serologic testing was negative in one of our patients despite demonstrating SARS-CoV-2 viral proteins/RNA in the patient's skin lesions. More studies are needed to determine why patients with COVID-19-associated perniosis could have negative antibody testing but the timing and sensitivity of the test and the individual immune response to the virus are all likely contributors. A similar type I interferon induced TH1 and monocyte response is seen in classic Kawasaki's disease and accounts for the T cell and monocyte-rich arteritis seen in these patients. By extension it is possible that the recently described a multiorgan Kawasaki like illness rarely seen in children with COVID-19 infection could develop as a result of excessively high levels of type I interferon . 1125, 26 In contradistinction, the minimal MXA expression in the skin biopsies from severe/critically ill COVID-19 patients suggests a lack of a type I interferon response. Certain disease states can suppress type I interferon response, including obesity which is associated with worse COVID-19 outcomes 27 .

The production of the adipokine leptin is proportionate to the body mass index, and its production is regulated by SOCS3. Terán-Cabanillas et al showed that when SOCS3 is upregulated in a high leptin state, in addition to leptin, it suppresses the Type I interferon response 28 . Type I interferons, unlike the more-discussed type II interferons (i.e. IFN ), can be induced in all cell types, but are silent in a state of health. In the case of COVID-19, Type I IFNs are induced by ssRNA of the virus binding to TLR7 and TLR8 in endosomes. The Type I

This article is protected by copyright. All rights reserved interferons produced are released and bind to the type I interferon homodimer receptor that is ubiquitous in the body 29 . This leads to a signaling through STAT1 and STAT2 that starts the production of a host of protective proteins, including IFITM3 which acts as a complement regulator 30 .

A polymorphism in IFITM3 has been shown to lead to poor outcomes in COVID-19 and is a topic that warrants further study 31 .

We propose that a strong type I interferon response may speed viral elimination whereas a blunted type I interferon response would allow for massive viral replication leading to complement activation through the mannan-binding lectin pathway. It has been noted that IFN-I response is often impaired in critically ill patients 31 and that association plays out in transcriptional analysis of interferon in SARS-CoV-2-infected, ACE2-expressing cells in vitro. 32 Not surprisingly, SARS-CoV-2 is susceptible to Type I interferon pretreatment in a yet unpublished study from Vineet Menachery 32 lending further credence to the benefits of a strong Type I interferon response. This hypothesis is shared by a group at Yale who wrote an editorial that reviewed some of the existing literature on COVID-19 associated perniosis and suggested its potential pathophysiologic commonality with idiopathic perniosis as a type of an interferonapathy although specific data supporting that hypothesis was not presented 34 .

The amount and microanatomic distribution of viral protein expression in COVID-19-associated perniosis in contrast to the thrombotic purpuric lesions of severe/critically ill COVID-19 reflects the importance of the antiviral effects of type I interferons. In perniosis cases studied, there was no expression of SARS CoV-2 protein in endothelium and only a few cells of probable monocytic lineage contained SARS CoV-2 protein and RNA. In the retiform thrombotic lesions, there was extensive localization of SARS CoV-2 protein in the endothelium although without any evidence of viral replication. There is evidence that the SARS CoV-2 spike protein is able to directly engage the MBL pathway, resulting in MASP-2 activation and the subsequent formation of the C3 convertase and ultimately C5b-9 (i.e. the membranolytic attack complex), the effector mechanism of endothelial cell injury and subsequent thrombosis that we and others have previously reported. 5,33,34 Furthermore

This article is protected by copyright. All rights reserved MBL activation leads to further systemic amplification of the alternative pathway and as well through well established feedback loop mechanisms, there is activation of the coagulation pathway. The striking expression of the proapoptotic marker caspase 3 likely reflects the sequelae of MBL activation which is known to result in apoptosis via caspase 3 activation. 35 The extensive degree of IL-6 upregulation could be due to its elaboration by endothelial cells via MBL activation as suggested in two separate studies. 36, 37 IL-6 may be involved in the pathogenesis of the vascular thrombosis through its effects on platelet aggregation and activation 38, 39 or upon angiotensin II regulation 40, 41 , or it may simply be a bystander resulting from hypoxia.

In conclusion, patients with COVID-19 associated perniosis demonstrate a robust immune reaction characterized by a T cell and interferon-rich microenvironment, that we believe leads to a mild course of the viral illness. The extent of interferon driven inflammation that can occur in children is clearly effective in eliminating virus but could also have deleterious consequences if unleashed in a multiorgan inflammatory context. In the pauci-inflammatory thrombosed skin of the very ill patients with COVID-19, interferon signaling is essentially absent, the implication being a permissive microenvironment that allows unchecked viral replication and triggers extensive complement activation of both the alternative pathway and MBL pathway with its catastrophic sequelae. This critically ill patient with severe Covid-19 demonstrates a mottled livedoid rash of the arms bilaterally(c).

This article is protected by copyright. All rights reserved 

Chilblains are a common cutaneous finding during the COVID-19 pandemic: a retrospective nationwide study from France

Acral cutaneous lesions in the Time of COVID-19

A case of COVID-19 presenting in clinical picture resembling chilblains disease. First report from the Middle East

Genetic and phenotypic spectrum associated with IFIH1 gain-of-function

Interferon-α in the generation of monocyte-derived dendritic cells: recent advances and implications for dermatology

Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant

Expression of CCR-7, MIP-3β, and Th-1 chemokines in type I IFNinduced monocyte-derived dendritic cells: Importance for the rapid acquisition of potent migratory and functional activities

Allograft Inflammatory Factor-1 Links T-Cell Activation, Interferon Response, and Macrophage Activation in Chronic Kawasaki Disease Arteritis

The transcriptional profile of coronary arteritis in Kawasaki disease

High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation

Role of Leptin and SOCS3 in Inhibiting the Type I Interferon Response During Obesity

Interferons at age 50: Past, current and future impact on biomedicine

Identification of differentially expressed transcripts targeted by the knockdown of endogenous IFITM3

Interferon-induced transmembrane protein-3 genetic variant rs12252-C is associated with disease severity in COVID-19

SARS-CoV-2 is sensitive to type I interferon pretreatment

Complement as a target in COVID-19?

Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation

Evaluation and clinical interest of mannan binding lectin function in human plasma

Influence of high glucose and mannose binding lectin complement pathway activation to IL-6 and TNF-alpha's expression by human renal glomerular endothelial cells

Mannose-binding lectin without the aid of its associated serine proteases alters lipopolysaccharide-mediated cytokine/chemokine secretion from human endothelial cells

Platelet activation and platelet-leukocyte aggregation elicited in experimental colitis are mediated by interleukin-6

Interleukin-6 mediates the platelet abnormalities and thrombogenesis associated with experimental colitis

IL-6 deficiency protects against angiotensin II-induced endothelial dysfunction and hypertrophy

Novel role of T cells and IL-6 (interleukin-6) in angiotensin IIinduced microvascular dysfunction

ACKNOWLEDGEMENTS We thank Dr. Ty Hanson from Sioux Falls, South Dakota for providing case material. We also thank Bing He from Weill Cornell Medicine, Department of Pathology and Laboratory Medicine and the TRP Research lab for their superb technical assistance and advise.